Shares of iBio (NYSEMKT: IBIO) climbed on Friday after the biotech announced plans to develop an intriguing second-generation vaccine candidate for COVID-19. By the close of trading, iBio's stock price was up 16.7% after rising as much as 41.3% earlier in the day.
iBio's experimental vaccine, IBIO-202, targets the nucleocapsid protein (N protein) of the novel coronavirus. N proteins tend to produce an immune response and remain relatively unchanged during mutations. By targeting the N protein, iBio hopes to develop a vaccine that will be highly effective against new coronavirus variants.
Image source: Getty Images.
For further details see:
Here's Why iBio Stock Surged Friday